

Nikhil V Patkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2028454/publications.pdf>

Version: 2024-02-01

76
papers

1,924
citations

623734

14
h-index

302126

39
g-index

81
all docs

81
docs citations

81
times ranked

958
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	7.2	1,211
2	A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2×10^{-6} and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 57-67.	1.5	52
3	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). <i>Leukemia</i> , 2021, 35, 1392-1404.	7.2	51
4	Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; OOB: 000-000. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 100-111.	1.5	47
5	Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 252-258.	1.5	36
6	Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy. , 2020, 8, e000630.		30
7	A one-step, one-tube real-time RT-PCR based assay with an automated analysis for detection of SARS-CoV-2. <i>Heliyon</i> , 2020, 6, e04405.	3.2	27
8	Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in <i>NPM1</i> mutated acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 36613-36624.	1.8	26
9	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 95-103.	3.3	24
10	A novel and easy <i>FxC</i> violet based flow cytometric method for simultaneous assessment of <i>DNA</i> ploidy and six-color immunophenotyping. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 281-291.	1.5	23
11	Mandatory preoperative COVID-19 testing for cancer patients: Is it justified?. <i>Journal of Surgical Oncology</i> , 2020, 122, 1288-1292.	1.7	21
12	Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol. <i>Blood Advances</i> , 2021, 5, 1178-1193.	5.2	19
13	Immunoprofile of Hodgkin's lymphoma in India. <i>Indian Journal of Cancer</i> , 2008, 45, 59.	0.2	17
14	<i>MYD88</i> mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. <i>Leukemia and Lymphoma</i> , 2015, 56, 420-425.	1.3	16
15	Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital. <i>Indian Journal of Cancer</i> , 2017, 54, 609.	0.2	15
16	Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 509-519.	1.5	14
17	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia: Real-World Context. <i>Frontiers in Oncology</i> , 2019, 9, 450.	2.8	14
18	Eleven-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 421-433.	1.5	14

#	ARTICLE	IF	CITATIONS
19	Characteristics of <i>BCR-ABL</i> kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. <i>Leukemia and Lymphoma</i> , 2016, 57, 2653-2660.	1.3	13
20	CD19 negative precursor B acute lymphoblastic leukemia (B-ALL) – Immunophenotypic challenges in diagnosis and monitoring: A study of three cases. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 315-318.	1.5	13
21	A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1. <i>Blood Cancer Journal</i> , 2019, 9, 79.	6.2	13
22	CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 328-335.	1.5	13
23	Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. <i>Frontiers in Oncology</i> , 2020, 10, 577.	2.8	13
24	An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia. <i>Indian Journal of Pathology and Microbiology</i> , 2017, 60, 209.	0.2	12
25	Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India. <i>Leukemia and Lymphoma</i> , 2012, 53, 609-615.	1.3	11
26	Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center. <i>JCO Global Oncology</i> , 2020, 6, 1684-1695.	1.8	11
27	MOLECULAR HETEROGENEITY IN ACUTE PROMYELOCYTIC LEUKEMIA - A SINGLE CENTRE EXPERIENCE FROM INDIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018002.	1.3	9
28	NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies. <i>Blood Cancer Journal</i> , 2020, 10, 50.	6.2	9
29	Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 434-445.	1.5	9
30	Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. <i>Indian Journal of Cancer</i> , 2018, 55, 9.	0.2	9
31	Machine learning derived genomics driven prognostication for acute myeloid leukemia with <i>RUNX1-RUNX1T1</i> . <i>Leukemia and Lymphoma</i> , 2020, 61, 3154-3160.	1.3	8
32	Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. <i>Indian Journal of Pathology and Microbiology</i> , 2018, 61, 209.	0.2	8
33	Utility of <i>CD36</i> as a novel addition to the immunophenotypic signature of <i>RAM</i> phenotype acute myeloid leukemia and study of its clinicopathological characteristics. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 206-217.	1.5	7
34	Sudden blast phase in pediatric chronic myeloid leukemia – chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: Can it be considered a warning sign?. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 345-351.	1.5	6
35	Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 3436-3444.	5.2	6
36	A 3½-Year-Old Child With a Posterior Fossa Mass. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 565-566.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Clinical course of severe COVID19 treated with tocilizumab and antivirals postâ€œallogeneic stem cell transplant with extensive chronic GVHD. Transplant Infectious Disease, 2021, 23, e13576.	1.7	5
38	A rare extramedullary and extralymphoid presentation of mixed phenotypic blastic hematolymphoid neoplasm: A study of two cases. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 394.	0.2	5
39	Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkinâ€™s Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India. Frontiers in Oncology, 2022, 12, 779230.	2.8	5
40	Immunogenetics of chronic lymphocytic leukemia. Indian Journal of Pathology and Microbiology, 2017, 60, 38-42.	0.2	5
41	Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)â€™A realâ€™world context. International Journal of Laboratory Hematology, 2021, 43, 1531-1538.	1.3	4
42	Expression of CD304/neuropilinâ€œ1 in adult bâ€™cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. International Journal of Laboratory Hematology, 2021, 43, 990-999.	1.3	4
43	Clinicoepidemiologic Profile and Outcome Predicted by Minimal Residual Disease in Children With Mixed-phenotype Acute Leukemia Treated on a Modified MCP-841 Protocol at a Tertiary Cancer Institute in India. Journal of Pediatric Hematology/Oncology, 2020, 42, 415-419.	0.6	4
44	Atypical Whipple's disease. Indian Journal of Gastroenterology, 2005, 24, 31.	1.4	4
45	Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma. International Journal of Hematology, 2020, 112, 835-840.	1.6	3
46	Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for Bâ€™lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease. British Journal of Haematology, 2022, 196, 374-379.	2.5	3
47	Adult T cell leukemia: A typical case from India. Indian Journal of Cancer, 2008, 45, 72.	0.2	3
48	Detecting hypodiploidy with endoreduplication and masked hypodiploidy in Bâ€™cell acute lymphoblastic leukemia using multicolor flow cytometry. Cytometry Part B - Clinical Cytometry, 2022, , .	1.5	3
49	Molecular basis of <sc>W</sc>iskottâ€™<sc>A</sc>ldrich syndrome in patients from India. European Journal of Haematology, 2012, 89, 356-360.	2.2	2
50	Investigating the clinical, hematological and cytogenetic profile of endoreduplicated hypodiploids in BCP-ALL. Blood Cells, Molecules, and Diseases, 2020, 85, 102465.	1.4	2
51	Mast cell differentiation of leukemic blasts in diverse myeloid neoplasms: A potential preâ€™myelomastocytic leukemia condition. Cytometry Part B - Clinical Cytometry, 2021, 100, 331-344.	1.5	2
52	Sequential Treatment of Arsenic Trioxide Followed by All Trans Retinoic Acid with Anthracyclines has Excellent Long-Term Cure in Acute Promyelocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 30-36.	0.6	2
53	Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 99-108.	1.1	2
54	SARS-CoV2 Infection in Hematopoietic Stem Cell Transplant recipients: A Case Series from a Tertiary Cancer Centre in India. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 699-701.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is influenced by the type of transport medium: Implications for diagnosis and monitoring. <i>International Journal of Clinical Practice</i> , 2021, 75, e14311.	1.7	2
56	'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'. <i>Indian Journal of Pathology and Microbiology</i> , 2016, 59, 407.	0.2	2
57	BRAFV600E mutation in hairy cell leukemia: A single-center experience. <i>Indian Journal of Pathology and Microbiology</i> , 2018, 61, 532.	0.2	2
58	Copy number gain of <i>JAK2</i> on marker chromosome in a case of relapsed pediatric B-ALL. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29658.	1.5	2
59	Development of a cost-effective duplexed real-time PCR assay for minimal residual disease monitoring of chronic myeloid leukemia using locked nucleic acid probes. <i>International Journal of Laboratory Hematology</i> , 2016, 38, e102-e106.	1.3	1
60	Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 808-816.	1.7	1
61	Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. <i>Medical Oncology</i> , 2020, 37, 48.	2.5	1
62	Lymphoblastic leukemia with surface light chain restriction: A diagnostic dilemma. <i>Indian Journal of Pathology and Microbiology</i> , 2016, 59, 410.	0.2	1
63	Parathyroid adenoma with ectopic intrathymic parathyroid—a case report. <i>Indian Journal of Pathology and Microbiology</i> , 2005, 48, 37-9.	0.2	1
64	Histopathology audit of chronic gastritis in India: need for objectivity and training. <i>Journal of Clinical Pathology</i> , 2006, 59, 554-554.	2.0	0
65	Clinical presentation & outcome of paediatric philadelphia-positive acute lymphoblastic leukaemia (Ph) Tj ETQq1 1 0.784314 rgBT /Over 2016, 1, S8-S9.	0.1	0
66	Cytogenetic profile and outcome of a pediatric acute promyelocytic leukemia patient presenting with isolated isochromosome 17q in absence of RARA rearrangement. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102443.	1.4	0
67	Importance of conventional cytogenetics in the identification of ins(19;X)(q13.1;p11.2q28) and t(1;11)(q10;p10), both, novel cytogenetic abnormalities in a pediatric AML case. <i>Cancer Genetics</i> , 2021, 256-257, 17-20.	0.4	0
68	Applicability of 2008 World Health Organization classification system of hematolymphoid neoplasms: Learning experiences. <i>Indian Journal of Pathology and Microbiology</i> , 2018, 61, 58.	0.2	0
69	A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2710-2710.	1.4	0
70	Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematolymphoid malignancies. <i>International Journal of Research in Medical Sciences</i> , 2020, 8, 1556.	0.1	0
71	Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study. <i>Blood</i> , 2020, 136, 26-26.	1.4	0
72	Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing. <i>Blood</i> , 2020, 136, 5-6.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai. International Journal of Clinical Practice, 2022, 2022, 1-9.	1.7	0
74	New cytologic features of solid and papillary epithelial neoplasms of the pancreas. Acta Cytologica, 2005, 49, 696-7.	1.3	0
75	Polyphenotypic peripheral neuroepithelioma occurring in the foot: a case report. Indian Journal of Pathology and Microbiology, 2007, 50, 29-32.	0.2	0
76	Biclonal chronic lymphocytic leukemia: A study of two cases and review of literature. Indian Journal of Pathology and Microbiology, 2017, 60, 84-86.	0.2	0